X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs PFIZER - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH PFIZER PANACEA BIOTECH/
PFIZER
 
P/E (TTM) x 145.3 28.8 505.1% View Chart
P/BV x 3.2 4.6 70.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   PFIZER
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
PFIZER
Mar-16
PANACEA BIOTECH/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1492,724 5.5%   
Low Rs821,611 5.1%   
Sales per share (Unadj.) Rs84.1440.9 19.1%  
Earnings per share (Unadj.) Rs-18.348.7 -37.6%  
Cash flow per share (Unadj.) Rs-6.775.8 -8.8%  
Dividends per share (Unadj.) Rs015.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs83.7462.9 18.1%  
Shares outstanding (eoy) m61.2545.75 133.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.44.9 27.9%   
Avg P/E ratio x-6.344.5 -14.2%  
P/CF ratio (eoy) x-17.228.6 -60.3%  
Price / Book Value ratio x1.44.7 29.5%  
Dividend payout %030.8 0.0%   
Avg Mkt Cap Rs m7,07499,163 7.1%   
No. of employees `0002.82.9 95.2%   
Total wages/salary Rs m1,4492,758 52.6%   
Avg. sales/employee Rs Th1,874.16,981.7 26.8%   
Avg. wages/employee Rs Th527.0954.5 55.2%   
Avg. net profit/employee Rs Th-407.7771.1 -52.9%   
INCOME DATA
Net Sales Rs m5,15420,170 25.6%  
Other income Rs m100857 11.6%   
Total revenues Rs m5,25421,028 25.0%   
Gross profit Rs m-7664,310 -17.8%  
Depreciation Rs m7111,239 57.4%   
Interest Rs m1,5035 28,903.8%   
Profit before tax Rs m-2,8813,923 -73.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,77199 1,791.1%   
Tax Rs m171,794 0.9%   
Profit after tax Rs m-1,1212,228 -50.3%  
Gross profit margin %-14.921.4 -69.6%  
Effective tax rate %-0.645.7 -1.3%   
Net profit margin %-21.811.0 -197.0%  
BALANCE SHEET DATA
Current assets Rs m3,81016,299 23.4%   
Current liabilities Rs m8,3657,594 110.2%   
Net working cap to sales %-88.443.2 -204.8%  
Current ratio x0.52.1 21.2%  
Inventory Days Days15665 238.5%  
Debtors Days Days6726 261.1%  
Net fixed assets Rs m14,4808,622 167.9%   
Share capital Rs m61458 13.4%   
"Free" reserves Rs m90320,722 4.4%   
Net worth Rs m5,12721,180 24.2%   
Long term debt Rs m5,83225 23,326.8%   
Total assets Rs m19,43329,137 66.7%  
Interest coverage x-0.9755.5 -0.1%   
Debt to equity ratio x1.10 96,360.4%  
Sales to assets ratio x0.30.7 38.3%   
Return on assets %2.07.7 25.6%  
Return on equity %-21.910.5 -207.9%  
Return on capital %3.619.0 19.1%  
Exports to sales %24.50.1 41,218.1%   
Imports to sales %10.217.5 58.3%   
Exports (fob) Rs m1,26412 10,531.7%   
Imports (cif) Rs m5253,526 14.9%   
Fx inflow Rs m1,53952 2,980.1%   
Fx outflow Rs m942140 673.0%   
Net fx Rs m597-88 -676.1%   
CASH FLOW
From Operations Rs m5993,436 17.4%  
From Investments Rs m-438-6,991 6.3%  
From Financial Activity Rs m-303-619 48.9%  
Net Cashflow Rs m-141-4,174 3.4%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.6 7.5 8.0%  
FIIs % 1.3 4.9 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 23.7 99.6%  
Shareholders   10,259 85,207 12.0%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 19, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS